In humans a pilot study using oral estriol to treat ten women with MS, six with relapsing-remitting (RR) MS and four with secondary-progressive (SP) MS (23), showed a decrease in IFN-gamma and active magnetic resonance imaging (MRI) lesions in the RRMS group. This evidence concerns the gene IFNG and myeloid sarcoma.